Clinical trial
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases
NCT06440746 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases
- Lead sponsor
- R-Pharm International, LLC
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- August 23, 2023
- Completion date
- December 25, 2028
- Enrollment
- 138 (estimated)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.